Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2003
09/11/2003US20030170328 Anti-inflammatory formulations
09/11/2003US20030170326 Bioavailability enchancing activity of Zingiber officinale Linn and its extracts/fractions thereof
09/11/2003US20030170324 Microencapsulated oil
09/11/2003US20030170322 Throat care agents
09/11/2003US20030170320 Extract is composed of carboxy alkyl esters, especially quinic acid lactone.
09/11/2003US20030170319 Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
09/11/2003US20030170318 Treating cancer by administering a fluoride or a salt thereof; e.g., sodium fluoride, calcium fluoride, magnesium fluoride, potassium fluoride, aluminum fluoride, strontium fluoride or sodium monofluorophosphate.
09/11/2003US20030170316 Treating asthma by preventing and/or accomodating for S-nitrosothiol breakdown
09/11/2003US20030170314 Carrier; and an atomically disordered, nanocrystalline metal-containing (especially silver) compound; may be antimicrobial, antinflammatory, anticancer, proapoptosis and/or an MMP modulating
09/11/2003US20030170312 Method for coating solid particles with a thermofusible agent, and resulting coated solid particles
09/11/2003US20030170310 Fexofenadine complexed with a carbomer; treating seasonal allergic rhinitis or chronic idiopathic urticaria
09/11/2003US20030170309 Pharmaceutical compositions containing polymer and drug assemblies
09/11/2003US20030170307 Inorganic-polymer complexes for the controlled release of compounds including medicinals
09/11/2003US20030170305 Sustained release over an extended period of time without an initial burst release of the agent(s) upon administration; outer layer of biodegradable polymer and inner portion of microcapsules formed from biodegradable polymer
09/11/2003US20030170304 Delivers an active ingredient in a pulsed or bimodal manner.
09/11/2003US20030170303 That has low water solubility such as celecoxib; and a release- extending polymer.
09/11/2003US20030170302 Permeable coating, preferably of water-permeable film-forming polymer (ethyl cellulose); a water-soluble polymer (polyvinyl pyrrolidone) and a plasticizer (stearic acid or dibutyl sebacate); specific dissolution profile
09/11/2003US20030170300 Combination chemotherapy
09/11/2003US20030170299 Therapeutic methods for acute myeloid leukemia
09/11/2003US20030170297 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
09/11/2003US20030170295 Hydrogel composition for transdermal drug delivery
09/11/2003US20030170294 Methods and devices for preventing transmission of sexually transmitted diseases
09/11/2003US20030170290 Reducing the problems of gastrointestinal irritation, dumping in the urine and bacterial degradation in oral administration
09/11/2003US20030170289 Injectable depot compositions and uses thereof
09/11/2003US20030170288 Drug delivery composition
09/11/2003US20030170287 Rapamycin or a rapamycin derivative having mTOR inhibiting properties
09/11/2003US20030170286 Codrug with at least two constituent moieties cleavably linked covalently to one another; dimensioned to position two radiation seeds a predetermined distance apart.
09/11/2003US20030170281 Cosmetic and dermatological preparations based on O/W emulsions
09/11/2003US20030170279 Emulsion vehicle for poorly soluble drugs
09/11/2003US20030170273 Type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules for enhancing the immune response of a coadministered antigen
09/11/2003US20030170258 Transmucosally administering an epitope which is located in close proximity to said immune response, wherein said modulation comprises induction of oral tolerization to said antigen.
09/11/2003US20030170235 Treatment with anti-ErbB2 antibodies
09/11/2003US20030170234 Combination of the antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin; treating cancer
09/11/2003US20030170233 Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody
09/11/2003US20030170225 Method of enhancing the effect of collagenase on wounds
09/11/2003US20030170223 Pulmonary vasodilator surfactant compositions and method of use
09/11/2003US20030170220 For inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia
09/11/2003US20030170216 SYN3 compositions and methods
09/11/2003US20030170211 For delivering alphavirus replicon DNA into an animal or animal cells with the replicon encoding one or more heterologous genes to be expressed in the animal or the animal cells
09/11/2003US20030170206 Interferon beta-like molecules
09/11/2003US20030170199 For care and prevention of the signs of ageing of the skin
09/11/2003US20030170196 Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
09/11/2003US20030170185 To enhance the remineralization
09/11/2003US20030170182 Topical spray for burn treatment and anti-infection
09/11/2003US20030170181 Method for preventing abuse of methylphenidate
09/11/2003US20030170178 For therapy and diagnosis of infectious diseases; diseases characterised by cellular hyperproliferation such as tumours, psoriasis, actinic keratosis, atheromas, endoarterial hyperplasia, prostate hyperplasia; for sterilization of blood
09/11/2003US20030170174 For therapy of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation; contrast agents
09/10/2003EP1343013A1 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents.
09/10/2003EP1342796A2 Compound for the treatment of paget's disease of bone
09/10/2003EP1342787A2 Arachidonic acid and methods for the production and use thereof
09/10/2003EP1342723A1 Indole derivatives and use thereof in medicines
09/10/2003EP1342721A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin
09/10/2003EP1342720A2 Epoxysuccinamide derivatives
09/10/2003EP1342718A1 Method and reagents for n-alkylating ureides
09/10/2003EP1342475A1 Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
09/10/2003EP1342474A1 The use of proline, poly-proline peptides and proline-rich proteins to quench reactive oxygen species
09/10/2003EP1342473A1 Esters of vitamin E as products for topical application
09/10/2003EP1342472A1 Analgesic and anti-inflammatory patches for external use containing 4-biphenylylylacetic acid
09/10/2003EP1342471A1 Nanocapsules based on polyol polyester, and cosmetic and dermatological compositions containing same
09/10/2003EP1342470A1 Fast release cefuroxime axetil compositions
09/10/2003EP1342469A2 Stable glass state powder formulations
09/10/2003EP1342462A1 O/w emulsion composition and method of preparing the same
09/10/2003EP1341923A2 Methods for enhancing the efficacy of cancer therapy
09/10/2003EP1341920A2 Human elongase genes and uses thereof
09/10/2003EP1341821A1 Thermoplastic and water soluble cellulose ether esters
09/10/2003EP1341813A1 Use of l-carnitine as stabilizing agent of proteins
09/10/2003EP1341811A2 Orally ingestible preparation of mistletoe lectins and method
09/10/2003EP1341800A2 C-glucosyl ether lipids
09/10/2003EP1341795A2 Novel labeled resiniferatoxin derivatives
09/10/2003EP1341793A2 Crf receptor antagonists and methods relating thereto
09/10/2003EP1341792A2 Amido ether substituted imidazoquinolines
09/10/2003EP1341791A2 Thioether substituted imidazoquinolines
09/10/2003EP1341790A2 Sulfonamido ether substituted imidazoquinolines
09/10/2003EP1341789A2 Aryl ether substituted imidazoquinolines
09/10/2003EP1341788A2 Pyrazolopyridines
09/10/2003EP1341787A2 Antimicrobial 2-pyridones, their compositions and uses
09/10/2003EP1341786A1 Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
09/10/2003EP1341784A2 Process for making a thrombin inhibitor
09/10/2003EP1341783A1 Isoquinoline derivatives useful in the treatment of cns disorders
09/10/2003EP1341782A2 Inhibitors of p38 kinase
09/10/2003EP1341781A1 Antimicrobial quinolones
09/10/2003EP1341779A2 Heterocyclic sulfonamide inhibitors of beta amyloid production
09/10/2003EP1341778A1 Klainetin and derivatives thereof, method for their production and the use of the same
09/10/2003EP1341777A2 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence
09/10/2003EP1341774A1 Fused heteroaromatic glucokinase activators
09/10/2003EP1341773A2 Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
09/10/2003EP1341771A2 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
09/10/2003EP1341770A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
09/10/2003EP1341769A2 Bacterial gyrase inhibitors and uses thereof
09/10/2003EP1341768A1 Therapeutic benzimidazole compounds
09/10/2003EP1341767A2 Imidazole and benzimidazole caspase inhibitors and uses thereof
09/10/2003EP1341766A1 Imidazolone derivatives for the treatment of viral diseases
09/10/2003EP1341765A1 Therapeutic compounds
09/10/2003EP1341764A1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
09/10/2003EP1341761A1 SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS
09/10/2003EP1341760A1 Sulfonylamino substituted 3-(aminomethylide)-2-indolinones as cell proliferation inhibitors
09/10/2003EP1341759A2 3-substituted oxindole beta 3 agonists
09/10/2003EP1341758A2 Coniosetin and derivatives thereof, method for producing the same and use thereof
09/10/2003EP1341755A1 Carboxylic acid amide derivatives and their use in the treatment of thromboembolic diseases and tumours
09/10/2003EP1341754A1 Substituted anthranilic acids
1 ... 5347 5348 5349 5350 5351 5352 5353 5354 5355 5356 5357 5358 5359 5360 5361 5362 5363 5364 5365 5366 5367 ... 7860